Results 61 to 70 of about 12,875 (250)

ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome

Haematologica, 2011
Background The assay for ADAMTS13 activity helps clinicians to confirm the clinical diagnosis of idiopathic thrombotic thrombocytopenic purpura. The clinical value of testing for the antigen level of ADAMTS13 protein is, however, less clear.Design and ...
Shangbin Yang, Ming Jin, Shili Lin, Spero Cataland, Haifeng Wu   +4 more
doaj   +1 more source

Von Willebrand Factor, ADAMTS13 and D-Dimer Are Correlated with Different Levels of Nephropathy in Type 1 Diabetes Mellitus. [PDF]

PLoS ONE, 2015
We have investigated whether von Willebrand factor, ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), and D-Dimer were associated with different levels of renal function in patients with type 1 diabetes. Patients
Caroline Pereira Domingueti, Luci Maria S Dusse, Rodrigo Bastos Fóscolo, Janice Sepúlveda Reis, Joyce Maria Annichino-Bizzacchi, Fernanda Loureiro de Andrade Orsi, Bruna de Moraes Mazetto, Maria das Graças Carvalho, Karina Braga Gomes, Ana Paula Fernandes   +9 more
doaj   +1 more source

Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS‐CoV‐2

International Journal of Laboratory Hematology, 2020
Dear Editors, Since early in 2020, the first people in Europe were infected with the SARS-CoV-2 virus leading to the COVID-2019 pandemic. In March 2020, we admitted the first patients with a SARS-CoV-2 infection in our hospital.
A. Huisman, R. Beun, M. Sikma, J. Westerink, N. Kusadasi   +4 more
semanticscholar   +1 more source

Crystal structure of ADAMTS13 CUB domains reveals their role in global latency

Science Advances, 2021
The crystal structure of the ADAMTS13 tandem CUB1 and CUB2 domains reveals how protease global latency is conferred. ADAMTS13 is a plasma metalloprotease that is essential for the regulation of von Willebrand factor (VWF) function, mediator of platelet ...
H. J. Kim, Y. Xu, A. Petri, K. Vanhoorelbeke, J. Crawley, J. Emsley   +5 more
semanticscholar   +1 more source

Special delivery for ADAMTS13 [PDF]

Blood, 2015
In this issue of Blood, using a transgenic mouse model, Pickens et al describe that ectopic expression of ADAMTS13, exclusively in platelets, is able to provide effective protection in murine models of arterial thrombosis and thrombotic thrombocytopenic purpura (TTP ...
openaire   +3 more sources

Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura

Haematologica, 2014
Anti-ADAMTS13 autoantibodies are the main cause of acquired thrombotic thrombocytopenic purpura. Binding of these antibodies to ADAMTS13 eventually results in the formation of antigen-antibody immune complexes.
Silvia Ferrari, Kristina Palavra, Bernadette Gruber, Johanna A. Kremer Hovinga, Paul Knöbl, Claudine Caron, Caroline Cromwell, Louis Aledort, Barbara Plaimauer, Peter L. Turecek, Hanspeter Rottensteiner, Friedrich Scheiflinger   +11 more
doaj   +1 more source

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.

Blood, 2020
Recently, we showed that during the acute phase of immune-mediated thrombotic thrombocytopenic purpura (iTTP), ADAMTS13 circulates in an open conformation. Although the cause of this conformational change in acute iTTP remains elusive, ADAMTS13 is mainly
E. Roose, A. Schelpe, E. Tellier, G. Sinkovits, B. Joly, C. Dekimpe, G. Kaplanski, M. le Besnerais, I. Mancini, Dr Tanja Falter, C. von Auer, H. Feys, M. Réti, H. Rossmann, A. Vandenbulcke, I. Pareyn, J. Voorberg, A. Greinacher, Y. Benhamou, H. Deckmyn, R. Fijnheer, Z. Prohászka, F. Peyvandi, B. Lämmle, P. Coppo, S. D. De Meyer, A. Veyradier, K. Vanhoorelbeke   +27 more
semanticscholar   +1 more source

Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura

EBioMedicine, 2015
Background: Acquired thrombotic thrombocytopenic purpura (TTP) is an autoimmune disease in which anti-ADAMTS13 autoantibodies cause severe enzyme deficiency.
Mari R. Thomas, Rens de Groot, Marie A. Scully, James T.B. Crawley   +3 more
doaj   +1 more source

Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP

Blood Advances
Key Points • Persistent detection of ADAMTS13 inhibitors may delay recovery of ADAMTS13 activity.• A delay in administering rituximab may potentially lead to further delays in the ADAMTS13 recovery.
Kenki Saito, K. Sakai, Masayuki Kubo, Hidekazu Azumi, Atsushi Hamamura, Shinichi Ochi, Hiroki Amagase, Hisako Kunieda, Yoshiyuki Ogawa, Hideo Yagi, M. Matsumoto   +10 more
semanticscholar   +1 more source

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.

Blood Advances, 2020
Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting.
L. Völker, J. Kaufeld, Wolfgang A. Miesbach, Sebastian Brähler, M. Reinhardt, Lucas Kühne, A. Mühlfeld, A. Schreiber, J. Gaedeke, M. Tölle, W. Jabs, Fedai Özcan, S. Markau, M. Girndt, F. Bauer, T. Westhoff, H. Felten, M. Hausberg, M. Brand, J. Gerth, M. Bieringer, M. Bommer, S. Zschiedrich, J. Schneider, S. Elitok, A. Gawlik, A. Gäckler, A. Kribben, V. Schwenger, U. Schoenermarck, M. Roeder, J. Radermacher, J. Bramstedt, A. Morgner, R. Herbst, Ana Harth, S. Potthoff, C. von Auer, R. Wendt, H. Christ, P. Brinkkoetter, J. Menne   +41 more
semanticscholar   +1 more source